{"id":10164,"date":"2025-05-25T11:24:55","date_gmt":"2025-05-25T09:24:55","guid":{"rendered":"https:\/\/oxfordwisefinance.com\/blog\/?p=10164"},"modified":"2025-05-25T11:25:05","modified_gmt":"2025-05-25T09:25:05","slug":"investor-caution-causes-dip-in-biotech-financing-report-finds","status":"publish","type":"post","link":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/","title":{"rendered":"Investor Caution Causes Dip in Biotech Financing, Report Finds"},"content":{"rendered":"

<\/p>\n

The latest figures for biotech financing<\/b> in the first quarter of 2025<\/b> reveal a significant downturn in investment activities within the sector. A total of $6.5 billion<\/b> was secured during the initial quarter, marking a decline from $8.1 billion<\/b> raised in the same timeframe in 2024<\/b>, as reported by GlobalData<\/b>, a prominent data analytics firm. The analysis indicates a total of 162 venture capital<\/b> investments were recorded, representing a 9% decrease<\/b> from the first quarter of last year. Notably, the primary therapeutic focus was in oncology<\/b>, which attracted 76 deals<\/b> from 217 investors<\/b>.<\/p>\n

GlobalData\u2019s report underscores the persistent challenges in raising venture capital financing<\/b>, suggesting that the current investment climate resembles downturns witnessed in 2022<\/b> and 2023<\/b>. Investors appear to be prioritizing later-stage companies<\/b> that can provide concrete clinical data<\/b>, thereby highlighting a cautious approach in funding decisions. This trend indicates a shift in investor preferences towards opportunities that promise shorter timelines for revenue generation<\/b> and market access<\/b> as opposed to engaging in the risks associated with longer-term developmental projects.<\/p>\n

According to Alison Labya, a GlobalData analyst<\/b>, \u201cThe higher deal values for late-stage firms<\/b> underscore a distinct realignment of investor risk appetite<\/b>\u2014a trend that has been observed since 2024.\u201d She elaborates that amidst ongoing macroeconomic uncertainties<\/a><\/b>, venture capitalists<\/b> are increasingly favoring investments with clearer paths to profitability rather than those laden with prolonged developmental risks.<\/p>\n

The onset of the second quarter of 2025<\/b> has already seen several significant financing rounds raised by firms in late-stage development<\/b>. Additionally, new companies emerging from stealth mode<\/b> have also managed to garner attention and interest from venture capital<\/b> investors. Below is a summary of notable financing news from the past month:<\/p>\n

\u2014Granite Bio has emerged from stealth mode, announcing a financing round totaling $100 million<\/b>, although not all of this amount is new funding.<\/strong> This financing package includes a $30 million Series A round<\/b> spearheaded by founding investors Versant Ventures<\/b> and Novartis Venture Fund<\/b>, alongside a $70 million Series B round<\/b> led by Forbion<\/b> and Sanofi Ventures<\/b>.<\/p>\n

Granite Bio\u2019s product pipeline features two innovative antibodies<\/b>, both of which have been developed through collaboration with Versant\u2019s Ridgeline Discovery Engine<\/b> based in Basel, Switzerland<\/b>. The first antibody, GRT-001<\/b>, acts as an inhibitor targeting the drivers of autoimmunity<\/b> and inflammation<\/b> known as monocytes<\/b>, and is currently undergoing Phase 1a testing<\/b> on healthy volunteers. The company is poised to initiate Phase 1b testing<\/b> for inflammatory bowel disease<\/b> later this year. The second antibody, GRT-002<\/b>, is designed to block interleukin-3<\/b>, a crucial signaling protein involved in inflammatory pathways associated with itch<\/b> and allergy<\/b> responses, with expectations to enter clinical trials by 2026<\/b>.<\/p>\n

\u2014Stately Bio, a biotech firm, has emerged from stealth mode, revealing it secured $12 million<\/b> in funding alongside an innovative AI-imaging platform<\/b> technology aimed at developing cell therapies<\/b> and regenerative medicines<\/b>.<\/strong> Based in Palo Alto, California<\/b>, this startup claims its platform differs from existing cellular imaging technologies that often damage cells, as it allows scientists to observe live cells, offering real-time insights without physical disruption.<\/p>\n

The company was founded by Frank Li<\/b>, who brought his machine learning<\/b> expertise from Alphabet\u2019s Calico Life Sciences<\/b>. Led by AIX Ventures<\/b>, Stately\u2019s seed financing will be utilized to expand its platform and to develop an internal pipeline of stem cell-derived therapies<\/b> targeting undisclosed conditions and indications.<\/p>\n

\u2014Flagship Pioneering has launched Etiome<\/b>, a startup dedicated to preemptively addressing diseases with drugs that target the earliest stages of disorders.<\/strong> Utilizing supervised artificial intelligence<\/b> applied to electronic health records and various data sources, Etiome identifies distinct biostages<\/b> of diseases, subsequently discovering drugs aimed at these critical temporal points. This innovative startup is supported by a financial backing of million<\/a><\/b> from Flagship.<\/p>\n

\u2014Glycomine successfully raised $115 million<\/b> to proceed with a placebo-controlled Phase 2b test<\/b> of GLM101<\/b>, an experimental treatment targeting phosphomannomutase 2-congenital disorder of glycosylation, a rare disease stemming from an enzyme deficiency.<\/strong> Instead of replacing the deficient enzyme associated with the disease, GLM101<\/b> aims to substitute a compound that is a vital component of its enzymatic process. The recent financing has been categorized under a Series C round<\/b>.<\/p>\n

\u2014Avidicure has been launched with $50 million<\/b> aimed at developing multifunctional antibody drugs<\/b> designed to leverage both the innate and adaptive immune systems to combat cancer.<\/strong> This Amsterdam-based biotech asserts that its drugs, termed AVC Boosters<\/b>, provide enhanced capabilities compared to currently available biologic drugs. The leading program, AVC-S-101<\/b>, targets the cancer protein TROP2<\/b> and is currently in development for non-small cell lung cancer and other solid tumor types. The seed financing for Avidicure was spearheaded by EQT Life Sciences<\/b>.<\/p>\n

\u2014Attovia Therapeutics has successfully secured $90 million<\/b> to propel its two lead programs through clinical proof of concept, specifically focusing on chronic pruritus<\/b> and atopic dermatitis<\/b>.<\/strong> This biotech firm, located in San Carlos, California<\/b>, has branded its innovative drugs as attobodies<\/b>, which are biologic drugs engineered with specialized properties. Deep Track Capital<\/b> was the leading force behind Attovia\u2019s Series C financing<\/b>.<\/p>\n

\u2014Imbria Pharmaceuticals, a developer of drugs targeting cardiometabolic diseases<\/b>, has closed $57.5 million<\/b> to advance its ninerafaxstat<\/b> treatment through Phase 2b testing<\/b> for non-obstructive hypertrophic cardiomyopathy.<\/strong> This oral small molecule drug acts as an inhibitor of partial fatty acid oxidation, encouraging a shift in the heart’s metabolic preference from fatty acids to glucose. Such a metabolic shift is designed to enhance cardiac function both at rest and during physical activity, with preliminary data anticipated by late 2026<\/b>. The Series B financing<\/b> for Boston-based Imbria was led by new investor Deep Track Capital<\/b>.<\/p>\n

\u2014Merida Biosciences, focused on immunology, has launched with $121 million<\/b> to support a robust pipeline led by an antibody-like drug currently in late preclinical development targeting Graves\u2019 disease<\/b>.<\/strong> Merida was founded with the backing of Third Rock Ventures<\/a><\/b>, which co-led the startup\u2019s Series A financing<\/b> alongside Bain Capital Life Sciences<\/b> and BVF Partners<\/b>.<\/p>\n

\u2014RayThera, a company engaged in the development of small molecule drugs for immunological applications, has raised $100 million<\/b> to advance its preclinical pipeline towards Phase 1 testing<\/b>.<\/strong> The company’s website lists three anti-inflammatory programs<\/b> targeting undisclosed objectives. The Series A financing<\/b> for the San Diego-based biotech was co-led by Foresite Capital<\/b> and OrbiMed Advisors<\/b>.<\/p>\n

\u2014Neurona Therapeutics has successfully raised $102 million<\/b> to propel its cell therapy NRTX-1001<\/b> into Phase 3 testing<\/b> for epilepsy.<\/strong> This therapy, derived from human pluripotent stem cells<\/b>, utilizes cells that secrete the inhibitory neurotransmitter GABA<\/b> to mitigate seizure activity effectively.<\/p>\n

\u2014Solu Therapeutics has secured an additional $41 million<\/b> in financing to develop innovative drugs that combine antibodies<\/b> and small molecules to target difficult-to-reach drug targets.<\/strong> Its lead program, STX-0712<\/b>, is currently undergoing Phase 1 testing<\/b> for chronic myelomonocytic leukemia and other blood cancers. This Boston-based biotech’s programs and technological platform were licensed from GSK<\/b>.<\/p>\n

\u2014HepaRegeniX has successfully completed a financing round totaling \u20ac21.5 million<\/b> (approximately $24.3 million<\/b>) to finalize an ongoing Phase 1b trial<\/b> and advance to Phase 2a testing<\/b> of HRX-215<\/b>, its lead candidate aimed at liver regeneration.<\/strong> This innovative drug is an oral small molecule that targets MKK4<\/b>, a key regulator of liver regeneration. Inhibiting this enzyme is expected to enhance the liver’s innate regenerative capabilities. The second close of financing added Wellington Partners<\/b> to the T\u00fcbingen, Germany-based biotech’s investment consortium.<\/p>\n

\u2014Atsena Therapeutics has raised $150 million<\/b> to support ongoing Phase 1\/2 tests<\/b> of ATSN-201<\/b>, a gene therapy targeted at addressing the vision disorder known as X-linked retinoschisis.<\/strong> The Series C financing<\/b> for Durham, North Carolina-based Atsena was led by new investor Bain Capital<\/b>.<\/p>\n

To stay updated on the latest trends in litigation, regulation, deals, and financial services, sign up for Finance Docket<\/b>, a collaboration between Breaking Media publications Above the Law<\/b> and Dealbreaker<\/b>.<\/em><\/p>\n

Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The latest figures for biotech financing in the first quarter of 2025 […]<\/p>\n","protected":false},"author":1,"featured_media":10165,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","pagelayer_contact_templates":[],"_pagelayer_content":"","iawp_total_views":2,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[142,328],"tags":[],"class_list":["post-10164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance-business","category-stock-investment","col-md-12"],"yoast_head":"\nInvestor Caution Causes Dip in Biotech Financing, Report Finds - Blog - Oxford Wise Finance<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investor Caution Causes Dip in Biotech Financing, Report Finds - Blog - Oxford Wise Finance\" \/>\n<meta property=\"og:description\" content=\"The latest figures for biotech financing in the first quarter of 2025 […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog - Oxford Wise Finance\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/instantpaydayloans\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-25T09:24:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-25T09:25:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/05\/Investor-Caution-Leads-to-Dip-in-Biotech-Financings-GlobalData-Report.png?fit=808%2C800&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"808\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Oxfordwisefinance\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/OxfordWiseLoans\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/\"},\"author\":{\"name\":\"Oxfordwisefinance\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"headline\":\"Investor Caution Causes Dip in Biotech Financing, Report Finds\",\"datePublished\":\"2025-05-25T09:24:55+00:00\",\"dateModified\":\"2025-05-25T09:25:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/\"},\"wordCount\":1253,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Investor-Caution-Leads-to-Dip-in-Biotech-Financings-GlobalData-Report.png?fit=808%2C800&ssl=1\",\"articleSection\":[\"Finance & Business\",\"Stock Investment\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/\",\"name\":\"Investor Caution Causes Dip in Biotech Financing, Report Finds - Blog - Oxford Wise Finance\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Investor-Caution-Leads-to-Dip-in-Biotech-Financings-GlobalData-Report.png?fit=808%2C800&ssl=1\",\"datePublished\":\"2025-05-25T09:24:55+00:00\",\"dateModified\":\"2025-05-25T09:25:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Investor-Caution-Leads-to-Dip-in-Biotech-Financings-GlobalData-Report.png?fit=808%2C800&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Investor-Caution-Leads-to-Dip-in-Biotech-Financings-GlobalData-Report.png?fit=808%2C800&ssl=1\",\"width\":808,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/investor-caution-causes-dip-in-biotech-financing-report-finds\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investor Caution Causes Dip in Biotech Financing, Report Finds\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\",\"name\":\"Blog - Oxford Wise Finance\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\",\"name\":\"Oxfordwisefinance\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"caption\":\"Oxfordwisefinance\"},\"sameAs\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/\",\"https:\\\/\\\/www.facebook.com\\\/instantpaydayloans\",\"https:\\\/\\\/x.com\\\/https:\\\/\\\/x.com\\\/OxfordWiseLoans\"],\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investor Caution Causes Dip in Biotech Financing, Report Finds - Blog - Oxford Wise Finance","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/","og_locale":"en_US","og_type":"article","og_title":"Investor Caution Causes Dip in Biotech Financing, Report Finds - Blog - Oxford Wise Finance","og_description":"The latest figures for biotech financing in the first quarter of 2025 […]","og_url":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/","og_site_name":"Blog - Oxford Wise Finance","article_author":"https:\/\/www.facebook.com\/instantpaydayloans","article_published_time":"2025-05-25T09:24:55+00:00","article_modified_time":"2025-05-25T09:25:05+00:00","og_image":[{"width":808,"height":800,"url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/05\/Investor-Caution-Leads-to-Dip-in-Biotech-Financings-GlobalData-Report.png?fit=808%2C800&ssl=1","type":"image\/png"}],"author":"Oxfordwisefinance","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/OxfordWiseLoans","twitter_misc":{"Written by":false,"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/#article","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/"},"author":{"name":"Oxfordwisefinance","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"headline":"Investor Caution Causes Dip in Biotech Financing, Report Finds","datePublished":"2025-05-25T09:24:55+00:00","dateModified":"2025-05-25T09:25:05+00:00","mainEntityOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/"},"wordCount":1253,"commentCount":0,"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/05\/Investor-Caution-Leads-to-Dip-in-Biotech-Financings-GlobalData-Report.png?fit=808%2C800&ssl=1","articleSection":["Finance & Business","Stock Investment"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/","url":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/","name":"Investor Caution Causes Dip in Biotech Financing, Report Finds - Blog - Oxford Wise Finance","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/#primaryimage"},"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/05\/Investor-Caution-Leads-to-Dip-in-Biotech-Financings-GlobalData-Report.png?fit=808%2C800&ssl=1","datePublished":"2025-05-25T09:24:55+00:00","dateModified":"2025-05-25T09:25:05+00:00","author":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"breadcrumb":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/#primaryimage","url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/05\/Investor-Caution-Leads-to-Dip-in-Biotech-Financings-GlobalData-Report.png?fit=808%2C800&ssl=1","contentUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/05\/Investor-Caution-Leads-to-Dip-in-Biotech-Financings-GlobalData-Report.png?fit=808%2C800&ssl=1","width":808,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/oxfordwisefinance.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Investor Caution Causes Dip in Biotech Financing, Report Finds"}]},{"@type":"WebSite","@id":"https:\/\/oxfordwisefinance.com\/blog\/#website","url":"https:\/\/oxfordwisefinance.com\/blog\/","name":"Blog - Oxford Wise Finance","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oxfordwisefinance.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36","name":"Oxfordwisefinance","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","caption":"Oxfordwisefinance"},"sameAs":["https:\/\/oxfordwisefinance.com\/","https:\/\/www.facebook.com\/instantpaydayloans","https:\/\/x.com\/https:\/\/x.com\/OxfordWiseLoans"],"url":"https:\/\/oxfordwisefinance.com\/blog\/author\/admin\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/05\/Investor-Caution-Leads-to-Dip-in-Biotech-Financings-GlobalData-Report.png?fit=808%2C800&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/10164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/comments?post=10164"}],"version-history":[{"count":2,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/10164\/revisions"}],"predecessor-version":[{"id":10167,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/10164\/revisions\/10167"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media\/10165"}],"wp:attachment":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media?parent=10164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/categories?post=10164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/tags?post=10164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}